Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of BAY 2328065 in Healthy Men
NCT04027192Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAY2328065 in endometriosis (6 arms), sponsored by Bayer. Primary endpoints: Number of subjects with treatment-emergent adverse events up to 45 days, Severity of treatment-emergent adverse events up to 45 days and 2 more. Started Jul 2019; status: completed.
02
Drugs
BAY2328065
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT04027192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027192.